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Abstract
Targeting PARP1 [Poly(ADP-Ribose) Polymerase 1] for synthetic lethality is a new strategy for BRCA germ-line mutated or
platinum sensitive ovarian cancers. However, not all patients respond due to intrinsic or acquired resistance to PARP1
inhibitor. Development of alternative synthetic lethality approaches is a high priority. DNA polymerase β (Polβ), a critical
player in base excision repair (BER), interacts with PARP1 during DNA repair. Here we show that polβ deficiency is a
predictor of platinum sensitivity in human ovarian tumours. Polβ depletion not only increased platinum sensitivity but also
reduced invasion, migration and impaired EMT (epithelial to mesenchymal transition) of ovarian cancer cells. Polβ small
molecular inhibitors (Pamoic acid and NSC666719) were selectively toxic to BRCA2 deficient cells and associated with
double-strand breaks (DSB) accumulation, cell cycle arrest and increased apoptosis. Interestingly, PARG [Poly(ADP-
Ribose) Glycohydrolase] inhibitor (PDD00017273) [but not PARP1 inhibitor (Olaparib)] was synthetically lethal in polβ
deficient cells. Selective toxicity to PDD00017273 was associated with poly (ADP-ribose) accumulation, reduced
nicotinamide adenine dinucleotide (NAD+) level, DSB accumulation, cell cycle arrest and increased apoptosis. In human
tumours, polβ-PARG co-expression adversely impacted survival in patients. Our data provide evidence that polβ targeting is
a novel strategy and warrants further pharmaceutical development in epithelial ovarian cancers.
Introduction
In BRCA germ-line deficient and platinum sensitive
sporadic epithelial ovarian cancers, PARP inhibitor (Nir-
aparib, Olaparib, Rucaparib) maintenance therapy improves
progression-free survival (PFS) [1–3]. However, not all
patients respond [4] either due to intrinsic resistance or
acquired resistance to PARP inhibitors. Therefore, the
development of alternative DNA repair targets and synthetic
lethality approaches is required.
Base excision repair (BER) is essential for the removal
of bases damaged by alkylation, oxidation or deamination
[5, 6]. BER is performed by at least two major sub-path-
ways: the short-patch pathway (SP-BER) and long-patch
pathway (LP-BER) [7]. Both pathways are initiated by a
* Srinivasan Madhusudan
srinivasan.madhusudan@nottingham.ac.uk
1 Translational Oncology, Division of Cancer & Stem Cells, School
of Medicine, University of Nottingham, Nottingham, UK
2 Medical Center, King Fahad Security College (KFSC),
Riyadh, Saudi Arabia
3 Academic Pathology, Division of Cancer & Stem Cells, School of
Medicine, University of Nottingham, Nottingham, UK
4 Department of Pathology, Faculty of Medicine, Menoufia
University, Menoufia, Egypt
5 Department of Oncology, Nottingham University Hospitals,
Nottingham, UK
6 Faculty of medicine and Health Sciences, Centre for Cancer
Sciences, University of Nottingham, Sutton Bonington Campus,
Sutton Bonington, Leicestershire, UK
7 Department of Pharmacology, Weill Cornell Medicine, New York,
NY, USA
8 Department of Anatomy and Cell Biology, College of Medicine,
University of Florida, Gainesville, FL, USA
Supplementary information The online version contains
















damage-specific DNA glycosylase, which removes the
damaged base creating an abasic site. APE1 then cleaves
the phosphodiester bond 5′ to the AP site thereby gen-
erating a nick with 5′-sugar phosphate (dRP) and 3′-
hydroxyl group. DNA polymerase β (polβ) adds the first
nucleotide to the 3′-end of the incised AP site. Normally,
the reaction continues through the short-patch repair
pathway where polβ removes the 5′-sugar phosphate
residue by the process of β-elimination [8] and DNA ligase
III-XRCC1 heterodimer (or DNA ligase I) then completes
the repair [9, 10]. Polβ-mediated lyase activity is the rate-
limiting step in SP-BER. The processing of oxidised AP
sites generates a 5′ residue that is resistant to β-elimination
(mediated by polβ) and therefore requires additional DNA
synthesis via LP-BER. A role for the polymerase activity
of Pol β under the coordination of the Rad9-Rad1-Hus1
sliding clamp complex (9-1-1 complex) in LP-BER has
also been described [10].
Polβ is a key player in BER [11]. Polβ interacts with
several components of the BER machinery including
XRCC1, ligase III and PARP1 to accomplish its biochem-
ical functions [11]. In the current study, we hypothesised
that Polβ could promising target in ovarian cancers.
Results
Polβ expression links to aggressive epithelial
ovarian cancers
A total of 379 tumours were suitable for analysis of
nuclear expression of polβ. 217/379 (57.3%) tumours
were low for polβ and 132/379 (42.7%) of tumours were
high in polβ expression (Fig. 1A). Low polβ expression
was more common in mucinous cystadenocarcinoma,
endometrioid and clear cell carcinomas (p= 0.001).
Whereas, high polβ expression was seen in sub-optimally
debulked (p= 0.023) (Supplementary Table 1). On the
other hand, FIGO stage I disease were more common in
tumours with low polβ expression (p= 0.003). Platinum
resistance was more common in tumours with high polβ
expression although it did not reach significance (p=
0.076). High polβ expression was associated with poor
PFS (p= 0.020) (Fig. 1B) and poor overall survival (OS)
(p= 0.029) (Supplementary Fig. S1A). At the transcrip-
tional level, similarly, high polβ mRNA expression was
associated with poor PFS and OS in both the test and
validation cohort 1 (all p values < 0.05) (Supplementary
Fig. S1). In the cancer genome atlas (TCGA) cohort
(Validation cohort 2), high polβ mRNA expression was
associated with poor PFS (Fig. 1C). Clinical data suggest
that high polβ is a marker of adverse phenotype. We
proceeded to pre-clinical studies.
Polβ localises to the nucleus after platinum
treatment in ovarian cancer cells
We chose A2780 (platinum sensitive) and A2780cis (pla-
tinum resistant) ovarian cancer cell lines for initial pre-
clinical studies [12] (Fig. 1D). To evaluate for alterations in
sub-cellular localisation of polβ upon cisplatin treatment,
we generated nuclear and cytoplasmic extracts at baseline
and following 48 h cisplatin therapy. We observed a sig-
nificant accumulation of polβ protein in the nucleus in
A2780cis cells compared A2780 cells (Fig. 1E) and (Sup-
plementary Fig. S2A). There was no alteration in cyto-
plasmic level of polβ protein in A2780 or A2780cis cells
(Fig. 1E) and (Supplementary Fig. S2A). For further vali-
dation, we monitored polβ sub-cellular localisation upon
cisplatin treatment using immunofluorescence assay at 24
and 48 h. As shown in Supplementary Fig. S2B, C, we
observed substantial nuclear accumulation of polβ after 48 h
of cisplatin treatment in A2780cis cells compared to A2780
cells. The data suggest that alterations in sub-cellular
localisation of polβ after platinum therapy may influence
sensitivity.
Bioinformatics analyses of the polβ interactome
As polβ mutants [13] have been reported previously to
influence biochemical function and platinum sensitivity,
we performed next generation exome sequencing and used
the variant effect predictor tool [14] to identify genetic
variants in platinum sensitive (A2780, PEO1) and plati-
num resistant (A2780cis, PEO4) cells (manuscript in pre-
paration). We did not observe any polβ variants in A2780,
A2780cis, PEO1 and PEO4 cells. While variants affecting
polβ functionally associated genes were not statistically
enriched in platinum-resistant cell lines, given the crucial
role of polβ as a mediator of platinum resistance, we next
examined loci encoding polβ-interacting proteins, as
defined in the BioGRID database [15] (Supplementary Fig.
S3A). Among these polβ interacting proteins, we identified
coding variants affecting LIG3, XRCC3, WRN; synon-
ymous variants affecting EP300, UNG, XPC and non-
coding variants affecting the APEX1, APTX, BCKDHA,
BCKDHB, HUS1, KTN1, NEIL1, RAD9A, SRPK2, SRPK2,
STUB1, TDP1, TLE1, TPP2, XPC, CRBN, TAF1D loci in
platinum resistant A2780cis and PEO4 cells compared to
platinum sensitive A2780 and PEO1 cells (Supplemental
Table 2). These include novel variants in EP300, HUS1,
KTN1, UNG, WRN, XRCC3 and XPC. Taken together, the
data suggest that polβ and variants affecting the polβ
functional interactome may contribute to platinum resis-
tance either directly or indirectly through interactions with
other factors involved in processing platinum induced
DNA damage.
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Polβ depletion increases platinum sensitivity
BER may operate predominantly during G1 phase of the
cell cycle [10]. Moreover, a BER complex (consisting of
polβ, APE1, UNG2 and XRCC1) was shown to physically
associate with MCM7 suggesting that BER may also
operate at sites of base damage and single-strand breaks
occurring at replication forks [16]. In addition, polβ activity
may also be prominent during the S-phase of the cell cycle
[17]. We therefore generated transient knockdowns (KD) of
polβ in A2780cis cells using siRNAs (Fig. 1F, Supple-
mentary Fig. S4A) and evaluated cell cycle progression in
control and polβ _KD cells. Compared to control cells,
we observed significant S-phase arrest in polβ_KD cells
(Fig. 1F) which was associated with accumulation of ATR
and pChk1ser 345 (Fig. 1G, H) and (Supplementary Fig. S4B,
C), a feature that would be consistent with replication stress
in A2780cis polβ_KD cells. In clonogenic assays,
Polβ_KD_A2780cis cells (transient KD generated using
siRNA) were strikingly sensitive to platinum therapy
(Fig. 1I). We also confirmed this observation using another
siRNA construct which also showed robust Polβ_KD and
also lead to platinum sensitisation (Supplementary Fig.
S4D, E). Polβ_KD was associated with double-strand break
Fig. 1 High Polβ expression is linked to aggressive ovarian can-
cers. A Immunohistochemical expression of Polβ in ovarian cancers.
B Kaplan–Meier curve for overall survival in: whole cohort.
C Kaplan–Meier curve for Polβ mRNA expression. D Cisplatin sen-
sitivity by clonogenic survival assay in A2780 and A2780cis. E Polβ
nuclear and cytoplasmic extracts in A2780 and A2780cis treated with
5 µM cisplatin. Lysates collected 48 h post treatment. F Polβ siRNA
knock down in A2780cis cells. Cell cycle analysis for A2780cis
control and Polβ_KD cells is shown here, G ATR and p-CHK1 protein
expression in A2780cis Polβ_KD cells. H Quantification of ATR and
p-CHK1 by western blot. I Cisplatin sensitivity by clonogenic survival
assay in A2780cis cells control and A2780cis_Polβ_KD cells.
J Quantification of γH2AX positive cells by flow cytometry in
A2780cis cells control and Polβ_knock down treated with 5 µM cis-
platin for 24 h. K Cell cycle analysis by flow cytometry in A2780cis
cells control and Polβ_knockdown treated with 5 μM cisplatin.
L AnnexinV analysis for apoptotic cells in A2780cis cells control and
Polβ_knock down treated with 5 μM cisplatin. For Flow cytometry
cells were seeded and transfected with scrambled control or Polβ
siRNA. At day 3 controls and knockdown cells were re platted in six-
well plates overnight and treated with 5 μM cisplatin and analyzed by
flow cytometry on day 5. Transfection efficiency was confirmed
by western blotting. Figures are representative of three or more
independent experiments.
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(DSB) accumulation (Fig. 1J), S-phase cell cycle arrest
(Fig. 1K) and apoptosis (Fig. 1L). We then tested in another
platinum resistant PEO4 ovarian cancer cells. As expected,
polβ depletion (Fig. 2A) and (Supplementary Fig. S4F)
increased platinum sensitivity (Fig. 2B) was associated with
increased γH2AX nuclear foci (Figs. 2C–E), 53BP1 foci
accumulation (Fig. 2F) S-Phase arrest (Fig. 2G) and apop-
totic cells (Fig. 2H). In platinum sensitive A2780 cells
treated with very low doses of cisplatin (nanomolar range),
again polβ depletion by SiRNA (Fig. 2I) and (Supplemen-
tary Fig. 4G) or with CRISPR-cas9 (Fig. 2J) resulted in
increased platinum sensitivity. We confirmed this result
using two siRNA constructs which showed robust polβ
knock down and similarly lead to platinum sensitisation
(Supplementary Fig. S4H, I). Polβ depletion increased
γH2AX nuclear foci accumulation (Fig. 2K, L) and
(Supplementary Fig. S5A), 53BP1 nuclear foci accumu-
lation (Fig. 2M), S-phase arrest (Fig. 2N) and apoptotic
cells (Fig. 2O).
We have tested another Isogeneic ovarian cancer cell line
model. PEO1, which is BRCA2 deficient, is a platinum
sensitive ovarian cancer cell line. We have recently
Fig. 2 Polβ depletion in ovarian cancer cell lines. A Polβ siRNA
transfection in PEO4 cells. B Cisplatin sensitivity by clonogenic sur-
vival assay in PEO4 scrambled control transfected cells and PEO4
Polβ_knockdown. PEO4 scrambled control and PEO4_Polβ_knock-
down cells were treated with 5 μM cisplatin and on day 5 cells were
analyzed by flow cytometry. C Representative photomicrographic
images for immunofluorescence staining of γH2AX and 53BP1 in
PEO4 scrambled control and polβ knockdown cells treated with 5 μM
cisplatin. D Quantification of γH2AX nuclear fluorescence by ImageJ
software. E Quantification of γH2AX positive cells by flow cytometry.
F Quantification of 53BP1 nuclear fluorescence by ImageJ software.
G Cell cycle analysis by flow cytometry. H Annexin V analysis by
flow cytometry. I Polβ siRNA transfection in A2780 cells and Cis-
platin sensitivity by clonogenic survival assay in A2780 scrambled
control and Polβ_Knockdown cells. J Polβ knock out by CRISPR-
Cas9 in A2780 cells and Cisplatin sensitivity by clonogenic survival
assay in A2780 control and Polβ_Knock out cells. K Quantification of
γH2AX nuclear fluorescence by ImageJ software. A2780 control and
A2780 Polβ_knock out cells were treated with 1 μM cisplatin and
analyzed by Immunofluorescence or flow cytometry on day 5.
L Quantification of γH2AX positive cells by flow cytometry.
M Quantification of 53BP1 nuclear fluorescence by ImageJ software.
N Cell cycle analysis by flow cytometry. O Annexin V analysis by
flow cytometry. A2780 control and Polβ_KO cells were plated over-
night and treated with 1 μM cisplatin for 24 h. After incubation, cells
were collected and stained as per the flow cytometry protocol detailed
in the methods. Figures are representative of three or more indepen-
dent experiments.
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generated a platinum resistant and PARP inhibitor (Ola-
parib) resistant cell line (PEO1R) from PEO1 cells. PEO1R
was generated by chronic exposure to an inhibitor of
MRE11 (mirin) over 6 months (Alblihy et al. manuscript
submitted). As shown in Supplementary Fig. S5B, PEO1R
is resistant to cisplatin treatment compared to PEO1 (Sup-
plementary Fig. S5B). Interestingly, Polβ knockdown in
PEO1R cells significantly increases sensitivity to cisplatin
(Supplementary Fig. S5B).
We then generated A2780cis polβ-knockout (KO) cells
using CRISPR-Cas-9 methodology (Fig. 3A) and (Supple-
mentary Fig. S5C). As shown in Fig. 3B, polβ_KO strik-
ingly increased sensitivity to platinum which was associated
increased nuclear γH2AX nuclear foci accumulation
(Fig. 3C, D) and (Supplementary Fig. S5D), 53BP1 foci
accumulation (Fig. 3E), S-phase arrest (Fig. 3F) and accu-
mulation of apoptotic cells (Fig. 3G). As platinum treatment
can induce the generation of free-radicals in cells and cause
oxidative DNA base damage, we also explored if the sensi-
tivity to cisplatin could be altered upon antioxidant treatment.
To address this hypothesis, we pre-treated cells with curcu-
min (antioxidant) for 24 h followed by cisplatin treatment.
Polβ deficient cells remained sensitive to platinum therapy
(Supplementary Fig. S6A). We then tested another DNA
cross-linker Mitomycin C. We again observed that polβ KO
cells were also sensitive to mitomycin C treatment (Supple-
mentary Fig. S6B). Together, the data provide evidence that
polβ is a predictor of platinum sensitivity.
Fig. 3 Polβ knock out increases platinum sensitivity. A Polβ
CRISPR_knockout in A2780cis cells. B Cisplatin sensitivity in
A2780cis control and Polβ-knockout cells. C Quantification of
γH2AX nuclear fluorescence by ImageJ software. D Quantification of
γH2AX positive cells by flow cytometry. E Quantification of 53BP1
nuclear fluorescence by imageJ software. F Cell cycle analysis by flow
cytometry. G Annexin V analysis by flow cytometry. For A2780cis
control and Polβ_knockout cells, Cells were treated with 5 μM cis-
platin for 24 h and analyzed by flow cytometry or cells were plated on
coverslips overnight and treated with 5 μM cisplatin for 24 h. Cells
were then fixed and stained for immunofluorescence as detailed in the
methods. All figures are representative of three or more experiments.
H BRCA2 and polβ expression by western blot in PEO1 and PEO4
cells. I Survival fraction in PEO1 and PEO4 control and Polβ_-
knockdown cells. J Representative photomicrographic images of
PEO1 and PEO4 control and Polβ_knockdown cells. K Quantification
of γH2AX nuclear fluorescence by ImageJ software. L γH2AX posi-
tive cells analysis by flow cytometry. M Quantification of 53BP1
nuclear fluorescence by ImageJ software. N Cell cycle analysis by flow
cytometry. O Annexin V analysis by flow cytometry. PEO1 and PEO4
control and Polβ_knockdown cells were transfected with Polβ SiRNA;
on day 4 cells were plated in six-well plates overnight and analyzed by
flow cytometry on day 5. Figures are representative of three or more
experiments.
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A role for Polβ in the regulation of invasion,
migration and EMT
There is also emerging evidence for the role of epithelial to
mesenchymal transition (EMT) in ovarian cancer che-
motherapy resistance [18]. To evaluate if polβ can also
influence the aggressive behaviour of ovarian cancer we
proceeded to investigate invasion, migration and EMT in
control and polβ_KO ovarian cancer cell lines. Polβ_KO in
A2780 and in A2780cis cells significantly reduced invasion
(Supplementary Fig. S7A). Given the well-defined roles of
E-cadherin [19], N-cadherin [20], TGFβ [21] and MMP-9
[22] in invasion and EMT regulation, we evaluated if polβ
could influence the expression of these key EMT markers
in ovarian cancer cells. As shown in Supplementary Fig.
S7B–D there was a clear induction of E-cadherin expression
in polβ_KO A2780 and A2780cis cells compared to control.
On the other hand, N-cadherin and MMP-9 were sig-
nificantly reduced in A2780 polβ_KO cells (Supplementary
Fig. S7B–D). TGFβ was significantly reduced in A2780cis
polβ_KO cells. Supplementary Fig. S7B–D. The data pro-
vide evidence that polβ may have a role in EMT. To provide
additional evidence we performed real-time PCR using RT2
Profiler EMT PCR Array for 86 EMT genes. Full list of
EMT genes included in the PCR array is summarised
in Supplementary Table S3. Compared to control cells,
downregulation of several genes with defined roles in EMT
was evident in polβ_KO cells (Supplementary Fig. S8A, B).
Interestingly, we also observed upregulation of some genes
with roles in EMT (Supplementary Fig. S8A, B). Together
the data would imply a complex role for polβ is influencing
the expression of genes involved in EMT.
Polβ blockade is synthetically lethal in BRCA2
deficient cells
BRCA2 is a key player in homologous recombination (HR).
Patients with germ-line mutations in BRCA2 are predis-
posed to ovarian cancer development with a cumulative life
time risk of about 20–30% [23]. PARP inhibitor main-
tenance therapy improves PFS in BRCA2 germ-line defi-
cient ovarian cancers [1–3]. However, not all patients
respond either due to intrinsic resistance or acquired resis-
tance to PARP inhibitors [4]. We hypothesised that polβ
could be a promising alternative synthetic lethality target in
BRCA2 deficient ovarian cancers. Polβ deficiency impairs
BER and leads to accumulation of single-strand breaks,
which if unrepaired, result in generation of DSBs during
replication. In cells deficient in HR repair (HRR), DSBs
would persist and lead to synthetic lethality. We therefore
tested synthetic lethality in BRCA2-deficient (PEO1) and
BRCA2-proficient (PEO4) ovarian cancer cells. PEO1
and PEO4 cells have robust Polβ expression (Fig. 3H) and
(Supplementary Fig. S9A). Cell viability, as investigated
by clonogenic assay, was significantly impaired when polβ
was depleted in PEO1 cells, but not in PEO4 cells (Fig. 3I).
Polβ depletion in PEO1 cells resulted in increased γH2AX
foci accumulation (Fig. 3J–L) 53BP1 foci accumulation
(Fig. 3M), S-phase cell cycle arrest (Fig. 3N) and induction
of apoptosis (Fig. 3O). We then tested cytotoxicity of polβ
inhibitors (polβi) in BRCA2-proficient and deficient cell
lines. Pamoic acid is a well described polβi [24]. The
cytotoxicity of Pamoic acid was first tested in control and
polβ_KO cells. We did not observe any significant cyto-
toxicity in polβ_KO cells compared to control cells (Sup-
plementary Fig. S9B). The data suggest that Pamoic acid
may have specific activity against polβ. Compared to
PEO4 cells, PEO1 cells were sensitive to Pamoic acid
treatment (Fig. 4A) which was associated with DSB
accumulation (Fig. 4B), S-phase arrest (Fig. 4C) and
apoptosis (Fig. 4D). We then validated Pamoic acid
activity in BRCA2 deficient and control HeLa cells
(Fig. 4E). As shown in Fig. 4F, Pamoic acid was selec-
tively toxic in HeLa BRCA2-deficient cells compared to
control HeLa cells. Increased sensitivity was associated
with DSB accumulation (Fig. 4G), S-phase arrest (Fig. 4H)
and increased apoptotic cells (Fig. 4I).
To recapitulate an in vivo system, we then generated 3D-
spheroids of PEO1, PEO4, HeLa control and HeLa
BRCA2_KD cells (Fig. 4J, K). BRCA2-proficient cells
(PEO4 and HeLa controls) and BRCA2-deficient cells
(PEO1 and HeLa BRCA2_KD cells) retain spheroid form-
ing capacity (Fig. 4J, K). However, upon Pamoic acid
treatment, in BRCA2-deficient spheroids, there was an
accumulation of apoptotic cells (Fig. 4L) as well as a
reduction in spheroid size (Fig. 4M) compared to BRCA2-
proficient spheroids (Fig. 4L, M). We then validated using
NSC666719 [4-chloro-5-methyl-N-[5-(naphthalen-2-yla-
mino)-1H1,2,4-triazol-3-yl]-2 sulfanylbenzenesulfona-
mide], another specific polβi [25–27]. In BRCA2 deficient
spheroids, NSC666719 treatment reduced spheroid size and
viability (Fig. 4J–M). NSC666719 treatment also resulted in
DSB accumulation (Supplementary Fig. S9C), G2/M cell
cycle arrest (Supplementary Fig. S9D) and apoptotic cells
(Supplementary Fig. S9E) in BRCA2-deficient cells com-
pared to BRCA2-proficient cells.
PARG inhibitor (PARGi) is selectively toxic in polβ
deficient cells
At sites of DNA damage, PARP1 is recruited where it
induces the synthesis of poly(ADP-ribose) (PAR). PAR-
ylation of PARP1 and other DNA repair factors is essential
for coordination of DNA repair [28]. PARylation is tran-
sient and reversible process. PAR glycohydrolase (PARG)
is a key factor in the PAR degradation pathway [29–31]
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A coordinated activity of PARP and PARG is also essential
for efficient DNA repair. Recently, PARG has also emerged
as a promising drug target in cancer [32, 33]. Importantly, a
recent study by Pillai et al. demonstrated that ovarian cancer
cells respond differently to PARGi (PDD00017273) com-
pared to PARPi (Olaparib) [34]. DNA replication vulner-
abilities was shown to particularly render ovarian cancer
cells sensitive to PDD00017273 treatment leading to per-
sistent replication fork stalling and replication catastrophe in
that study [34]. As polβ-deficient ovarian cancer cells are
not only sensitive to platinum treatment but also show
features of replication stress as evidenced by accumulation
of ATR and pChk1ser 345, we tested a synthetic lethality
application for either PARPi or PARGi. We first evaluated
cellular activity of Olaparib and PDD00017273 in
polβ-deficient and -proficient ovarian cancer cells. Olaparib
did not induce selective cytotoxicity in polβ_KO or control
cells (Supplementary Fig. S9F, G). However, as shown in
Fig. 5A, B, PDD00017273 treatment was selectively toxic
in polβ_KO A2780 or polβ_KO A2780cis cells compared
to controls. To also validate this observation in PEO4
ovarian cancer cell line, we generated transient knockdown
of polβ and again observed increased sensitivity to
PDD00017273 treatment in PEO4 cells (Supplementary
Fig. S9H). We proceeded to functional studies to under-
stand potential mechanisms of PDD00017273 toxicity.
Fig. 4 Polβ inhibitors induce synthetic lethality in BRCA2 deficient
ovarian cancer cells. A Pamoic acid sensitivity by clonogenic sur-
vival assay in PEO1 and PEO4 cells. B γH2AX analysis by flow
cytometry for PEO1 and PEO4 cells treated with Pamoic acid (250â€
‰μM). C Cell cycle analysis by flow cytometry in PEO1 and PEO4
cells treated with Pamoic acid (250â€‰μM) for 24â€‰h. D Annexiγn
V analysis by flow cytometry in PEO1 and PEO4 cells treated with
Pamoic acid (250â€‰μM) for 24â€‰h. E BRCA2 western blot in
HeLa control and HeLa BRCA2_knockdown cells. F Pamoic acid
sensitivity in HeLa control and HeLa BRCA2_knock down cells by
clonogenic survival assay is shown here. γH2AX analysis by flow
cytometry (G), cell cycle analysis by flow cytometry (H) and annex-
inV analysis by flow cytometry (I) in HeLa control and HeLa
BRCA2_knockdown cells treated with Pamoic acid (250â€‰μM) for
24â€‰h. Representative photomicrographic images of Pamoic acid
(250â€‰μM) and NSC666719 (250â€‰μM) treated 3D-spheres of:
PEO1 and PEO4 cells (J), HeLa control and HeLa (BRCA2_KD) (K).
L Quantification of spheroids cell viability by flow cytometry.
M Quantification of spheroids size by ImageJ. Figures are repre-
sentative of three or more experiments. Error bars represent standard
deviation between experiments.
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Mechanistic studies of PARGi in polβ-deficient cells
At baseline, there were no changes in PARP1 levels in
both control and polβ_KO cells (Fig. 5C, Supplementary
Figs. S9I, S10A). However, in polβ_KO cells there was a
reduction in PAR level compared to control cells (Fig. 5D)
and (Supplementary Fig. S11B, C). Using PARG ELISA
assay we show that polβ_KO cells have increased PARG
activity compared to control cells (Fig. 5E). We then
evaluated PAR level in polβ_KO and controls treated with
either Olaparib or PDD00017273 (Fig. 5F) and (Supple-
mentary Fig. S10D, E). In Olaparib-treated cells, as
expected, there was a reduction in PAR levels in both
control and polβ_KO cells which also confirmed in a PAR
ELISA assay (Supplementary Fig. S10G). PDD00017273
treatment increased PAR level in control and polβ_KO
cells (Fig. 5F) and (Supplementary Fig. S10D–F). To
further validate, we monitored PAR level by confocal
microscopy at 1, 6, and 24 h following PDD00017273
treatment in A2780_ polβ_KO and control cells
(Fig. 5G–I). In A2780 control cells, following PDD00017273
treatment, there was transient increase in PAR accumulation
at 6 h which returned to baseline levels at 24 h compared to
untreated cells. However, in A2780_ polβ_KO cells, there
Fig. 5 Polβ knock out cells is sensitive to PARG inhibitor. A PARG
inhibitor sensitivity by clonogenic survival assay in A2780 control and
Polβ_knock out cells. B PARG inhibitor sensitivity by clonogenic
survival assay in A2780cis control and Polβ_knock out cells. C Polβ,
PARP1 levels by western blot in A2780 and A2780cis control and
Polβ_knockout cells. D Poly (ADP) ribose polymers levels in A2780
and A2780cis control and Polβ_knock out cells. E PARG ELISA
assay in A2780 control, A2780 (Polβ_KO), A2780cis control and
A2780cis (Polβ_KO) cells. F Poly (ADP) ribose polymers levels in
A2780 and A2780cis control and Polβ_knock out cells treated with
Olaparib or PARG inhibitor. Cells were treated with Olaparib (10 μM)
or PARGi (20 μM) for 16 h then extracted for western blot.
G Immunofluorescence staining for poly (ADP) ribose polymers in
A2780 control and Polβ_knockout cells untreated or treated with
PARGi (20 μM) for 1, 6, and 24 h. H, I Quantification of Poly (ADP)
ribose polymers fluorescence by imageJ software. J Quantification of
NAD+ levels in A2780 and A2780cis control and Polβ_knock out
cells. K Representative photomicrographic images of 53BP1 and
γH2AX immunofluorescence in A2780 and A2780cis control and
Polβ_knock out cells treated with PARGi (20 μM) for 16 h. L Quan-
tification of γH2AX nuclear fluorescence by ImageJ software.
M Quantification of 53BP1 nuclear fluorescence by ImageJ software.
N p-CHK1 levels by western blot in A2780 and A2780cis control and
Polβ_knock out treated with Olaparib (10 μM) or PARGi (20 μM) for
16 h. Figures are representative of three or more experiments. Error
bars represent standard deviation between experiments.
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was accumulation of PAR at 24 h compared to untreated
cells (Fig. 5G–I). PARP1 catalyses the polymerisation of
ADP-ribose units (PAR) from NAD+. On the other hand,
PARG catalyses the hydrolysis of PAR producing free
mono- and oligo(ADP-ribose) [28]. We evaluated NAD+
levels in untreated as well as PDD00017273-treated con-
trol and polβ_KO cells (Fig. 5J). In untreated A2780_
polβ_KO cells, there was a significant increase in NAD+
levels compared to control cells. Upon PDD00017273
treatment there was a significant reduction in NAD+
levels in A2780_ polβ_KO cells compared to controls.
Interestingly in untreated A2780cis_ polβ_KO cells, there
was no increase in NAD+ levels compared to controls.
However following PDD00017273 treatment NAD+
levels significantly reduced compared to controls
(Fig. 5J). Together, the data suggest a complex cell line
dependent network operating between polβ, PAR and
NAD+. Previous studies have shown that PAR accumu-
lation can not only impair efficient DNA repair but can
also be directly toxic to cells [35, 36]. Depletion of
NAD+ is known to alter NAD+/SIRT1 axis which also
leads to impaired DNA repair and cell survival [37, 38].
PDD00017273 treatment in A2780_polβ_KO cells pro-
moted γH2AX nuclear foci accumulation (Fig. 5K, L) and
(Supplementary Fig. S11G), an indirect biomarker for
DSBs and replication stress-induced defects. As a further
validation of DSBs, we also observed 53BP1 nuclear foci
accumulation in PDD00017273-treated A2780_polβ_KO
cells (Fig. 5K, M). Consistent with PDD00017273
induced replication arrest, CHK1 was phosphorylated on
serine 345 in PARGi-treated polβ deficient cells (Fig. 5N,
Supplementary Fig. S10H), which was then associated
with S-phase arrest (Fig. 6A) and induction of apoptosis
(Fig. 6B). Similarly, in A2780cis_ polβ_KO cells com-
pared to controls, PDD00017273 treatment was associated
with γH2AX nuclear foci accumulation (Fig. 6C, D),
53BP1 nuclear foci accumulation (Fig. 6E), increased
phosphorylated CHK1 (Fig. 5M, Supplementary Fig.
S10H), S-phase arrest (Fig. 6F) and apoptosis (Fig. 6G).
In 3-D spheroid models, PDD00017273 treatment reduced
spheroid size and promoted cell death in polβ_KO
spheroids compared to control spheroids (Fig. 6H–J).
Olaparib did not influence cell viability in 3-D spheroid
assays (Fig. 6H–J). Together the data suggest that PARGi
in polβ deficient induces selective cytotoxicity through
replication stress, DSB accumulation and cell death.
Talazoparib, has at least 100 times more potency to trap
PARP at replication forks compared to Olaparib [28]. As
expected, A2780_polβ_KO and A2780cis_ polβ_KO cells
were sensitive to Talazoparib therapy compared to con-
trols (Supplementary Fig. S11A, B). The data would
suggest that replication stress induction contributes to the
observed cytotoxicity.
Clinicopathological significance of PARG expression
in human ovarian cancers
PARG expression was cytoplasmic. Low PARG expression
was seen in 60/274 (22%) tumours and high PARG
expression was observed in 214/274 (72%) of tumours. High
PARG expression was associated with serous cystadeno-
carcinomas (p= 0.011) (Supplementary Table S4). PARG
expression did not influence PFS (Supplementary Fig.
S12A). However, high PARG expression was associated
with poor OS in the whole cohort (p= 0.032) (Supplemen-
tary Fig. S12B). The data suggest that PARG may have
prognostic significance in ovarian cancers. We then per-
formed polβ/PARG co-expression analysis. Polβ/PARG co-
expression was associated with serous cystadenocarcinomas
(p= 0.017) and higher stage (p= 0.004) (Supplementary
Table S5). Tumours with high polβ/PARG co-expression
have poor PFS (Fig. 6K) (p= 0.041) as well as OS (Fig. 6L)
(p= 0.045) compared to tumours with low polβ/PARG co-
expression. In multivariate analyses (Supplementary Table
S6), polβ (p= 0.012) and platinum sensitivity (0.0001)
independently influenced PFS. Platinum sensitivity remained
independently linked to OS (p= 0.0001) (Supplementary
Table S6). PARG expression was borderline non-significant
in multivariate analysis (p= 0.051 and 0.056 respectively)
(Supplementary Table S6).
Discussion
Polβ, a member of the X-family of DNA polymerases is a
key player in BER [10]. Pre-clinically we demonstrated
that polβ depletion increased platinum sensitivity in plati-
num resistant A2780cis, PEO4 and PEO1R ovarian cancer
cells. In platinum sensitive A2780 cells, although there
were some variations due to different experimental condi-
tions, Polβ depletion using multiple siRNA constructs
consistently increased platinum sensitivity. Interestingly, in
cisplatin untreated A2780cis cells polβ deficiency caused
S-phase arrest and a replication arrest phenotype. However,
we did not observe this phenomenon in A2780 or PEO4
cells, implying a cell line dependent role for polβ during
replication in ovarian cancer cells.
Higher levels of polβ have been described in colonic and
prostate compared with normal tissue [39, 40]. Mutations in
polβ may influence aggressive solid tumour phenotype and
response to chemotherapy [13]. In ovarian cancers, muta-
tions in polβ have been recognised [41] although clinical
significance remains unclear [41]. In clinical cohorts of
ovarian cancers, we show that low Polβ expression is
associated with better PFS. In the current study, we did not
observe any cytoplasmic staining for polβ protein in ovarian
tumours. For nuclear expression, we have observed some
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peri-nuclear or annular staining for polβ. Whether this
represents altered polβ expression or variable polβ expres-
sion due to DNA damage is unknown but will be an inter-
esting area for further exploration in the future. Importantly,
we provide evidence that low polβ expression at the protein
as well as at the mRNA levels is linked with better PFS.
Polβ deficiency in mice is embryonically lethal [42] and
embryonic fibroblasts derived from such mice are hyper-
sensitive to alkylating agents [43]. Depletion of polβ
delayed the repair of oxaliplatin-induced DNA damage and
increased sensitivity in colorectal cancer cell lines [44]. On
the other hand, polβ overexpression increased resistance to
DNA-damaging agents [45]. Our data concur with a pre-
vious study in colorectal cell lines showing platinum sen-
sitivity with polβ depletion [46].
Chronic platinum exposure can alter function of
microtubules and microfilaments and can reduce migration
[47, 48], a feature also seen in A2780cis cells. We show
that wild-type cells have expression of N-Cadherin, TGFβ.
and MMP9. Polβ depletion reduced N-Cadherin, TGFβ,
and MMP9 levels along with induction of E-cadherin.
Cadherin switch is the hallmark of EMT [49]. TGFβ and
MMP-9 also have a role migration/invasion [49]. Whilst
downregulation of several EMT genes was also evident in
polβ-depleted cells, we speculate an indirect role for polβ
in EMT which require future mechanistic study con-
firmation. Interestingly, previous studies show PARP1
depletion [50] and Histone H2AX depletion [51] in pro-
moting EMT through transcriptional regulation suggesting
a complex role for DNA repair in EMT.
Fig. 6 Mechanisitc studies of PARG inhibitor in ovarian cancer.
A Cell cycle analysis by flow cytometry. B Annexin V analysis by flow
cytometry for A2780 cells control and Polβ_knockout cells treated with
20 μM PARGi for 24 h. C Representative photomicrographic images for
53BP1 and γH2AX immunofluorescence staining in A2780 control and
Polβ_knockout cells treated with 20 μM PARGi. D Quantification by
γH2AX nuclear fluorescence by ImageJ software. E Quantification of
53BP1 nuclear fluorescence by ImageJ software. F Cell cycle analysis by
flow cytometry. G Annexin V analysis by flow cytometry. A2780cis
cells control and Polβ_knockout cells were treated with 20 μM PARGi
for 24 h cells were collected and analysed as per the flow cytometry
protocol or cells were seeded on coverslips and treated with PARGi
(20 μM) for 24 h before staining for immunofluorescence protocol.
H Representative photomicrographic images for A2780 control and
Polβ_knockout spheroids treated with Olaparib (10 μM) or PARGi
(20 μM). I, J Quantification of spheroids cell viability is shown here.
Figures are representative of three or more independent experiments.
K Polβ and PARG co-expression and Kaplan–Meier curve for ovarian
cancer progression-free survival (PFS). L Polβ and PARG co-expression
and Kaplan–Meier curve for overall survival in ovarian cancer.
R. Ali et al.
In the current study we not only observed increased nuclear
localisation of polβ following cisplatin treatment but basal
levels of polβ protein also appears to be higher in platinum
resistant cells. Although we did not identify any activating
mutations of polβ, we speculate that post transcriptional or
translational mechanisms could result in overexpression of
polβ. Another interesting observation was that despite the lack
of polβ variants, bioinformatics analyses revealed several key
polβ-interacting proteins harboured novel non-synonymous
variants, affecting the LIG3, WRN and XRCC3 loci. However,
a limitation to the current study is that further detailed func-
tional and mechanistic studies would be required to fully
evaluate if polβ functional interactome may contribute to
platinum resistance in ovarian cancer cells.
We show that polβi can induce synthetic lethality in
BRCA2-deficient cells. Although promising, future in vivo
xenograft studies are required to confirm our findings. PARG
blockade is also selectively toxic in polβ-deficient cells. Polβ
depletion or inhibition increase SSBs. PARG is essential for
efficiency of SSB repair [52]. In polβ deficient cells we
observed increased PARG activity. PARG inhibition or
depletion can also increase reversed replication forks and
post-replicative single-strand breaks [32, 33]. In polβ defi-
cient cells with impaired BER and increased SSB, PARG
inhibition leads to profound accumulation of SSBs which get
converted to DSB leading to synthetic lethality. Accordingly,
we observed DSB accumulation, S-phase arrest and apop-
tosis in PDP00017273-treated polβ-deficient cells compared
to -proficient cells. Additionally, PARG inhibition was
associated with accumulation of PAR polymers in
polβ-deficient cells. Accumulation of PAR was accompanied
by NAD+ depletion via two potential mechanisms; (1)
PARP uses NAD+ as ADP-ribose donor and catalyse
PARylation of target proteins including itself. 2) PARG
mediates rapid turnover of PAR to mono-ADP-ribose units
which is recycled as the ATP precursor, an important sub-
strate to generate NAD+. PARGi will therefore increase
NAD+ [31]. PARG mediated reversal of auto-modification
of DNA bound PARP1 leads to poly-ubiquitination of
PARP1 by the E3 ligase CHFR. Removal and degradation
of PARP1 contribute further to the restoration of NAD+
levels. In PARGi-treated cells, therefore, reduced level of
NAD+ may persists [53]. There are at least two mechanisms
for NAD+ depletion induced cell death; (1) caspase-
independent programmed necrosis, where excess PAR acti-
vates apoptosis-inducing factor, which triggers the apoptotic
cascade [35, 36]. (2) NAD+ depletion can alter Sirtuin level
and impair BER [37, 38] contributing further to SSB accu-
mulation. Moreover, PAR accumulation is also known to be
toxic to cells and can also impair DNA repair [35]. However,
it should be noted that persistent accumulation of PAR
polymers in A2780 Polβ_KO cells but transient formation of
PAR polymers in the control A2780 was observed in the
current study. The exact molecular mechanisms of this
phenomenon are not clear although an increased level of
PAR formation is expected with inhibition of PARG (which
hydrolyses PAR polymers). As described, PAR accumula-
tion and NAD depletion can contribute directly and indir-
ectly to the impairment of DNA machinery, which could be
more lethal in the context of polβ deficiency [54, 55]. A
recent study proposed that loss of PARG activity is a pos-
sible mechanism for PARPi resistance in BRCA2 deficient
tumours. PARG operates in the same direction as PARPi by
preventing PAR accumulation. Hence, decreased PARG
activity can allow tumour cells to escape the PARPi medi-
ated synthetic lethality [29]. These findings concur with
our observations in polβ deficient ovarian cancer cells.
Another study by Pillay et al. has revealed that ovarian
cancer cells respond differently to PARGi (PDD00017273)
compared to PARP inhibitor (Olaparib) and may be depen-
dent on DNA replication vulnerabilities in cells [34].
Therefore endogenous PARG levels could predict Olaparib
response in HR deficient as well as in polβ deficient ovarian
cancer cells. PARGi is also synthetically lethal in BRCA1
[32], BRCA2, PALB2, FAM175A and BARD1 deficient
breast cancer cells [33].
In conclusion, polβ blockade is a novel approach war-
rants for development in ovarian cancers.
Materials and methods
Full details are available in Supplementary material and
methods.
Clinical study
Polβ immunohistochemistry was completed in 525 epithelial
ovarian cancers. Polβ mRNA expression in human epithelial
ovarian was investigated in three ovarian tumour gene
expression data sets [test set, validation cohort 1 and vali-
dation cohort 2 (TCGA). See Supplementary methods for full
details. Ethical approval which was obtained from the Not-
tingham Research Ethics Committee (REC Approval Num-
ber 06/Q240/153). All patients provided informed consent.
Pre-clinical study
A2780, A2780cis, PEO1 and PEO4 were purchased from
American Type Culture Collection (ATCC, Manassas,
USA). BRCA2-deficient HeLa SilenciX cells and controls
BRCA2-proficient HeLa SilenciX cells were purchased
from Tebu-Bio (www.tebu-bio.com).
Methodology for transient knockdown of Polβ and
generation of Polβ knockouts are described in Supplemen-
tary methods.
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Compounds, reagents, clonogenic assays, cell prolifera-
tion assays, confocal microscopy, functional assays (FACS,
cell cycle progression, apoptosis assays. ELISA), invasion
assay, migration assay, 3D-spheroid assays, next generation
sequencing and bioinformatics are described in Supple-
mentary methods.
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